Inomagen Therapeutics, Inc. is focused on developing innovative gene therapies specifically aimed at treating Atrial Fibrillation (AF), a prevalent heart rhythm disorder. The company is pioneering a non-viral gene therapy that addresses the root causes of AF, which current treatments often fail to target effectively. To facilitate safe and efficient gene delivery, Inomagen is creating a patented transcatheter gene delivery system. This approach is designed to enhance the therapeutic outcomes for patients suffering from AF, particularly as the condition becomes more common in an aging population.

The company has established a strong foundation for its scientific advancements through significant non-dilutive grant funding and has secured an exclusive licensing agreement with Northwestern University, which provides access to a robust intellectual property portfolio. Inomagen's team comprises experienced professionals from various sectors of the healthcare and biotechnology industries, all dedicated to bringing these transformative therapies to market. Their operations are based in Chicago's Fulton Market, within a biotech incubator that offers state-of-the-art laboratory facilities to support their research and development efforts.

United States

Inomagen Therapeutics is a private, preclinical-stage biotechnology company developing a non-viral gene therapy that targets the underlying mechanisms of atrial fibrillation.

Inomagen Therapeutics, Inc.

Company Details